N/A
Average UserN/A
Average AnalystVery Bullish
Stock Target AdvisorUSD 0.08
0.00 (0.00)%
USD 8.59B
1.99M
N/A
N/A
Average UserN/A
Average AnalystVery Bullish
Stock Target AdvisorUSD 8.59B
USD 0.08
Based on the Mylan N.V stock forecasts from 0 analysts, the average analyst target price for Mylan N.V is not available over the next 12 months. Mylan N.V’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Mylan N.V is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Mylan N.V’s stock price was USD 0.08. Mylan N.V’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredien...Read More
1.47
N/A
11.15
N/A
47,144,965
USD 16.12
46,489,413
USD 16.42
0.91%
11.05%
90.50%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
|
PPD Inc | 0.00 (0.00%) | USD16.61B | 47.04 | 21.58 |
|
Viatris Inc | +0.10 (+0.82%) | USD14.42B | 18.02 | 6.97 |
|
Neurocrine Biosciences Inc | -0.71 (-0.64%) | USD10.41B | 180.48 | 98.51 |
|
Tilray, Inc | 0.00 (0.00%) | USD6.86B | 60.60 | 454.68 |
|
Momenta Pharmaceuticals, Inc | 0.00 (0.00%) | USD6.24B | N/A | N/A |
|
Alkermes Plc | +0.05 (+0.17%) | USD4.73B | N/A | -72.85 |
|
Intracellular Th | -0.10 (-0.21%) | USD4.45B | N/A | -14.58 |
|
Lantheus Holdings Inc | +1.14 (+1.98%) | USD3.86B | 36.91 | 16.96 |
|
Evotec SE ADR | +0.10 (+1.03%) | USD3.66B | 508.00 | -19.09 |
|
HUTCHMED DRC | +0.73 (+4.05%) | USD3.64B | 17.69 | -6.38 |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
|
VanEck Vectors Generic Dr.. | 4.43 % | 0.55 % | 0.00 (0.00%) | USD3.35M |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.